https://vitasmlab.net

SEPMARK

Serine Proteases Targeted Library

Serine proteases are essential enzymes that cleave peptide bonds, regulating critical processes like blood clotting, diges- tion, immune response, and tissue remodeling. Their dysregulation contributes to major diseases, including thrombosis, inflammatory disorders, cancer metastasis, and viral infections. Current serine protease inhibitors, such as anticoagulants and antiviral drugs, often lack specificity, leading to side effects like bleeding risks or limited efficacy against resistant strains. The rise of drug-resistant pathogens and complex chronic diseases demands novel therapeutics targeting disease-specific serine proteases with higher precision. Next-generation small molecular inhibitors could transform treatment for cardiovas- cular diseases, autoimmune conditions, and emerging viral threats, addressing unmet needs in precision medicine. Innova- tive serine protease-targeted drugs are crucial to overcoming therapeutic challenges and improving outcomes for millions of patients worldwide.





STK723162



STK870472



STK312449

Serine Proteases Targeted Library (SEPMARK) consists of compounds with potential activity against serine proteases. Compounds were selected based on similarity to known effectors of human serine proteases. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. It is designed in a way that maximizes structur- al diversity and excludes problematic compounds. This library has 3630 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at
irina@vitasmlab.biz
Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!
Empowering Your Research, One Molecule at a Time.